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Live attenuated vaccines (LAVs) have prevented morbidity and mortality against a number of 
important viral diseases (such as smallpox and polio) via long-lived humoral and cell-mediated 
immunity. Unlike inactivated, subunit or recombinant protein vaccines which require multiple 
inoculations this cost-effective approach requires only one or two doses to generate a robust immune 
response (Graham and Crowe, 2007). Furthermore, live vaccines are able to elicit both mucosal and 
systemic protective responses. Unfortunately, conventional LAVs have two major drawbacks. Firstly, 
attenuation of the pathogenic phenotype by either random gene mutation or by passage in unnatural 
conditions depends on chance and cannot be universally applied to a variety of virus types. Secondly, 
since viruses are generally attenuated on the basis of only a few mutations the risk of reversion to 
virulence remains a key aspect of developing attenuated virus vaccines.  
Novel methods to rationally design vaccines include control by microRNAs (miRNAs) or zinc finger 
nucleases (ZFNs). While each of these may be useful against persistent or latent viruses, miRNAs and 
ZFNs are limited to RNA and non-integrating DNA viruses respectively (Lauring et al., 2010). Two 
other approaches have been recently proposed. In one approach, increased replication fidelity of error-
prone RNA polymerases through mutations, reduces the likelihood of reversion from attenuation to 
wild type (Vignuzzi et al., 2008). A second approach, dubbed synthetic attenuated virus engineering 
(SAVE), can be used to create non-virulent strains of viruses, which could provide a platform 
technology for vaccine development against a wide variety of viral diseases (Coleman et al., 2008; 
Wimmer et al., 2009; Mueller et al., 2010). The new vaccine strategy exploits the fact that the genetic 
code is degenerate in that most amino acids are encoded by more than one three-nucleotide codon 
(e.g. GCA, GCC, GCG, and GCT all code for the amino acid alanine). Many organisms, including 
viruses, tend to have biases toward certain synonymous codons (the “codon bias”) and codon pairs 
(the “codon pair bias”) in their genes (Gutman and Hatfield, 1989; Moura et al., 2007; Tats et al., 
2008). Codon pair bias refers to the preferential pairing of certain codons over others (e.g. in human 
genes the codon pair GCC-GAA encodes the adjacent amino acids alanine-glutamic acid less often 
than GCA-GAG, even though GCC and GAA are the most used codons, Coleman et al., 2008). 
Unfavourable host codon pairs introduced into a viral genome may adversely affect protein translation 
and thereby provide a method for producing attenuated viruses. 
As a proof of concept for SAVE, a team led by Eckard Wimmer at Stony Brook University used a 
computer-guided approach to design weakened poliovirus strains (Coleman et al., 2008). The research 
is an outgrowth of a technique they pioneered to assemble the virus from scratch (Cello et al., 2002). 
The single stranded positive-sense RNA genome of poliovirus contains a long open reading frame 
encoding a polyprotein that is cleaved into P1 (capsid precursor), P2 and P3 (precursors to non-
structural proteins) flanked by 5’ and 3’ nontranslated regions. Briefly, they engineered the P1 coding 
region (encoding the viral capsid, 2643 nucleotides) with under- or over-represented codon pairs:  the 
attenuated strains caused decreased rates of protein translation and protected mice challenged with a 
lethal dose of wild-type poliovirus (Figures 1 & 2, vide infra). The promising results of this work 
suggested that SAVE could play a role in creating new vaccines for influenza virus. The “flu” virus 
genome is composed of eight segments of negative-sense RNA that encode up to 12 proteins. 
Segments targeted for attenuation encode proteins that play important roles in replication and 
assembly of influenza virus - nucleoprotein (NP), polymerase subunit B1(PB1), and hemagglutinin 
(HA). Synthetic strains of influenza virus PR8 containing one (NP, HA, or PB1), two (NP/HA or 
HA/PB1) or three (PB1/NP/HA, short PR8
3F
) codon pair deoptimized gene segments formed plaques 
and grew in vitro. The PR8
3F 
strain was highly attenuated in vivo and could protect mice challenged 
with wild-type influenza virus (Mueller et al., 2010). 
As a general strategy for vaccine development, SAVE offers several advantages. First, because this 
approach involves the introduction of hundreds of “silent” mutations, unlike the handful of mutations 
found in current vaccine strains, the probability of reversion of codon-pair deoptimized vaccines to 
virulence is essentially zero. Second, given the changes do not alter the amino acid sequences, the 
proteins expressed are identical to wild type virus and possess identical immunogenic properties. 
Finally, as attenuation is systematic rather than empiric, it can be applied speedily to a wide range of 
viruses in various species. 
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